3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with pirenzepine in 9 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (pirenzepine) | Trials (pirenzepine) | Recent Studies (post-2010) (pirenzepine) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 3,812 | 587 | 140 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | pirenzepine (IC50) |
|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.6891 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.5856 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.6134 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.6222 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.6227 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.6227 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.3406 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.6281 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0291 | |
| Muscarinic acetylcholine receptor M1 | Mus musculus (house mouse) | 0.75 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.9556 | |
| Muscarinic acetylcholine receptor M4 | Mus musculus (house mouse) | 0.75 | |
| Muscarinic acetylcholine receptor M5 | Mus musculus (house mouse) | 0.75 | |
| Muscarinic acetylcholine receptor M3 | Mus musculus (house mouse) | 0.75 | |
| Muscarinic acetylcholine receptor M2 | Mus musculus (house mouse) | 0.51 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busatto, GF; Costa, DC; Ell, PJ; Kerwin, RW; Nohria, V; Pilowsky, LS; Sharma, T; Sigmundsson, T; Taylor, M | 1 |
| Asenbaum, S; Barnas, C; Brücke, T; Fischer, P; Kasper, S; Küfferle, B; Pezawas, L; Tauscher, J; Tauscher-Wisniewski, S | 1 |
| Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K | 1 |
| Egan, MF; Knable, MB; Lafargue, T; Pickar, D; Raedler, TJ; Urbina, RA; Weinberger, DR | 1 |
| Booij, J; Gersons, BP; Lavalaye, J; Linszen, DH; Reneman, L; van Royen, EA | 1 |
| Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D | 1 |
| Dresel, S; Frodl, T; Hahn, K; Mager, T; Meisenzahl, EM; Möller, HJ; Preuss, UW; Rossmüller, B; Schmitt, GJ; Tatsch, K | 1 |
| Bernardo, M; Catafau, AM; Font, M; Gómez, JC; Gutiérrez, F; Lomeña, F; López-Carrero, C; Parellada, E; Pavía, J; Salamero, M | 1 |
| Dresel, S; Frodl, T; Hahn, K; Meisenzahl, EM; Möller, HJ; Preuss, UW; Rossmüller, B; Schmitt, GJ; Tatsch, K | 1 |
5 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and pirenzepine
| Article | Year |
|---|---|
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Clozapine; Contrast Media; Corpus Striatum; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Olanzapine; Pirenzepine; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Brain; Brain Mapping; Contrast Media; Female; Humans; Iodine Radioisotopes; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Brain; Brain Chemistry; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2000 |
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Double-Blind Method; Female; Frontal Lobe; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Prospective Studies; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2001 |
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Dopamine D2 Receptor Antagonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2002 |
4 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and pirenzepine
| Article | Year |
|---|---|
Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Corpus Striatum; Haloperidol; Humans; Middle Aged; Olanzapine; Pirenzepine; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1996 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studies; Corpus Striatum; Dopamine Antagonists; Female; Humans; Iodine Radioisotopes; Male; Olanzapine; Pirenzepine; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1999 |
In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.
Topics: Adult; Benzamides; Benzodiazepines; Case-Control Studies; Contrast Media; Corpus Striatum; Dose-Response Relationship, Drug; Female; Humans; Male; Olanzapine; Parkinson Disease, Secondary; Pirenzepine; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Tomography, Emission-Computed, Single-Photon | 1999 |
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Corpus Striatum; Female; Health Status; Humans; Iodine Radioisotopes; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 2000 |